Dynamic 3d-mr mammography: Is there a benefit of sophisticated evaluation of enhancement curves for clinical routine?
✍ Scribed by Markus Müller-Schimpfle; Katja Ohmenhäuser; Jürgen Sand; Peter Stoll; Claus D. Claussen
- Book ID
- 102905525
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 917 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1053-1807
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The purpose of the study was to compare standard analysis with pharmacokinetic analysis of time‐intensity curves in dynamic three‐dimensional (3D) MR mammography (MRM) for their capability of differentiating benign from malignant disease. Dynamic MRM of the whole breast was performed at 1.0 T using an axial fast low‐angle shot (FLASH) 3D sequence. For the standard evaluation, the enhancement of the first minute (E~1~) and the slope of enhancement from minute 2 to 10 (SE~2–10~) were calculated. For pharmacokinetic analysis, the amplitude of enhancement (A), distribution time (t~21~), and elimination time (t~el~) were computed. Sixty‐two histologically verified lesions were evaluated. The standard evaluation methods yielded a highly significant difference between benign and malignant disease for E~1~ (P = .0008) and SE~2–10~ (P = .0001). The pharmacokinetic parameters gained similarly significant P values (A, P = .0014; t~21~, P = .0024; t~el~, P = .0001). Both standard and pharmacokinetic analysis concordantly discriminated between benign and malignant lesions in discriminant analysis. Compared with standard analysis, a pharmacokinetic analysis of time‐intensity curves is not beneficial for routine clinical diagnosis.